MedTrace Logo

Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD

NCT02812862 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2022-10-27

No results posted yet for this study

Summary

The aim of this study is to evaluate the pulmonary and cardiac effects of the LABA / LAMA combination Tiotropium / Olodaterol therapy in patients suffering from both congestive heart failure and chronic obstructive pulmonary disease.

Conditions

Interventions

DRUG

Spiolto® Respimat® (Tiotropium / Olodaterol)

LABA/ LAMA combination therapy: A combination of two bronchodilators acting on two separate pharmacological targets - one ß-agonist and one anti-muscarinergic agent.

Sponsors & Collaborators

  • RWTH Aachen University

    lead OTHER

Principal Investigators

  • Michael Dreher, MD · University Hospital, Aachen

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-08-31
Completion
2018-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02812862 on ClinicalTrials.gov